Plus Therapeutics Extends Cash Runway, Advances CNS Cancer Therapies
Event summary
- Plus Therapeutics raised $15 million in an upsized public offering, extending its cash runway to support CNSide commercialization and REYOBIQ development.
- Secured AMA Category III CPT reimbursement code for REYOBIQ, unlocking market access for recurrent glioblastoma and pediatric brain cancer treatments.
- Expanded CNSide laboratory licensing to 49 U.S. states, covering approximately 95% of the U.S. population.
- Announced national coverage agreements with Humana and UnitedHealthcare, reaching approximately 67 million people.
- Reported a net loss of $22.4 million for 2025, with cash and investments balance at $13.1 million as of December 31, 2025.
The big picture
Plus Therapeutics is positioning itself at the forefront of targeted radiotherapeutics for CNS cancers, leveraging strategic partnerships and regulatory milestones to drive market access. The company's focus on both commercial scale-up and clinical development reflects a dual-pronged approach to addressing unmet needs in a niche but critical segment of oncology. With a strengthened cash position, Plus Therapeutics aims to balance aggressive growth with financial sustainability.
What we're watching
- Clinical Development
- The pace at which REYOBIQ advances through Phase 2 trials and secures FDA alignment on pivotal trial design will determine its commercial viability.
- Commercial Scale-Up
- Whether CNSide can achieve breakeven by 2027 hinges on expanding payer coverage and increasing test orders.
- Financial Sustainability
- How Plus Therapeutics manages rising R&D and administrative expenses amid increasing commercial operations will impact its long-term financial health.
Related topics